In Vivo Pharmacology

Metabolic Disease


We provide in vivo models simulating widely prevalent metabolic diseases. These models may be used for assessing potential of molecules to reduce /prevent these diseases. We offer the following models:

  • NAFLD/NASH
    Model
    High fat (60Kcal%) and high fructose (40% in water) induced NAFLD/NASH in C57Bl/6 mice
    Test System
    C57Bl/6 mice
    Method
    week 1 to week 12: the animals fed with High fat (60Kcal%) and high fructose (40% in water) (induction period) After induction period the grouping based on body weight Administration of test item and reference item at predetermined time (usually 28 days)
    End Point
    • Body weight and feed intake
    • Plasma glucose and lipid levels
    • Fat pad weight
    • Histopathology evaluation (liver samples)
    • ALT, AST and Insulin (optional)
    Model
    Methionine- and choline-deficient (MCD)deficient diet C57Bl/6 mice
    Test System
    ob/ob/C57Bl/6 mice
    Method
    week 1 to week 8-10: the animals fed with Methionine- and choline-deficient (MCD)deficient diet (induction period) After induction period the grouping based on body weight Administration of test item and reference item at predetermined time (usually 28 days)
    End Point
    • Body weight and feed intake
    • Plasma glucose and lipid levels
    • Fat pad weight
    • Histopathology evaluation (liver samples)
    • ALT and AST levels
    X
  • Obesity
    Model
    High fat diet (60%) induced obesity in C57Bl/6 mice (secondary model)
    Test System
    C57Bl/6 mice
    Method
    week 1 to week 12: the animals fed with High fat (60Kcal%) (induction period) After induction period the grouping based on body weight Administration of test item and reference item at predetermined time (usually 28 days)
    End Point
    • Body weight and feed intake
    • Plasma glucose and lipid levels
    • Fat pad weight
    • Histopathology evaluation (liver samples)
    Model
    Spontaneous (genetically modified) (ob/ob) mice
    Test System
    ob/ob mice
    Method
    Randamisation based on body weight Administration of test item and reference item at predetermined time (usually 28 days)
    End Point
    • Body weight and feed intake
    • Plasma glucose and lipid levels
    • Fat pad weight
    • Histopathology evaluation (liver samples)
    Model
    Spontaneous (genetically modified) Zucker (obese) rat
    Test System
    Zucker (obese) rat
    Method
    Randamisation based on body weight Administration of test item and reference item at predetermined time (usually 28 days)
    End Point
    • Body weight and feed intake
    • Plasma glucose and lipid levels
    • Fat pad weight
    • Histopathology evaluation (liver samples)
    Model
    DIO (diet induced obesity) model
    Test System
    DIO mice (C57BL/6)
    Method
    3-4 weeks mice will be fed with high fat diet (60Kcal%) for 12 weeks (induction period) At the end of induction period the animals will be selected based on body weight (the animals shows significant increase in body weight compared to normal control) Administration of test item and reference item at predetermined time Body weight and feed intake will be recorded on daily basis. Oral glucose tolerance test (OGTT) will be carried out at the end of the experiment
    End Point
    • Body weight, feed intake, plasma glucose and lipid levels (triglycerides and cholesterol) , Fat pad weight and OGTT
    X
  • Dyslipidaemia
    Model
    High fat (23 %) ,High cholesterol (0.5%) diet and 10 % fructose (in drinking water) induced dyslipidaemia in Golden Syrian hamsters
    Test System
    Golden Syrian hamsters
    Method
    High fat (23 %) ,High cholesterol (0.5%) diet and 10 % fructose (in drinking water) (induction period) After induction period the grouping based on triglycerides (TG)and total cholesterol (TC) Administration of test item and reference item at predetermined time (usually 14 days)
    Test System
    • Body weight Plasma glucose and lipid levels (TG, TC and non esterified fatty acid (NEFA)
    X
  • Diabetes (type I)
    Model
    STZ induced type I diabetes
    Test System
    Sprague- Dawley rat
    Method
    The animals will be fasted for 15 – 18 hrs , after basal blood glucose measurement , the animals injected with STZ 40- 45 mg/kg single dose i.p. Two weeks post injection the animals shows blood glucose levels (fed glucose) between 250 – 350 mg/dl will be selected for the main experiment Administration of test item and reference item at predetermined time Body weight and feed intake will be recorded on daily basis. At the end of the experiment plasma/serum samples will be collected for further analysis
    Test System
    • Body weight, feed intake, plasma glucose and lipid levels (triglycerides and cholesterol)
    X
  • Diabetes (type II)
    Model
    Spontaneous (genetically modified) diabetic (db/db)mice
    Test System
    db/db mice
    Method
    Randamisation based on blood glucose levels Administration of test item and reference item at predetermined time (usually 28 days)
    Test System
    • Body weight and feed intake
    • OGTT (oral glucose tolerance test)
    • Plasma glucose , lipid and insulin levels and HbA1c
    • Fat pad weight
    • Histopathology evaluation (Pancrease)
    Model
    Spontaneous (genetically modified) diabetic Zucker (fa/fa) rat
    Test System
    Zucker (fa/fa) rat
    Method
    Randamisation based on blood glucose levelsAdministration of test item and reference item at predetermined time (usually 28 days)
    Test System
    • Body weight and feed intake OGTT (oral glucose tolerance test)Plasma glucose , lipid, insulin levels and HbA1c Fat pad weight Histopathology evaluation (Pancrease)
    X
  • In-Vivo Model for Test Item on Diabetes Induced Nephropathy
    Model
    Repeated low dose STZ induced diabetes
    Test System
    Male C57BL6 Mouse
    Method
    • Repeated low dose STZ induction
    • 2-3 week diabetes stabilization
    • Test item administration
    • Biochemical analysis
    Test System
    • Body weight
    • Glucose, Glycated Hb & Urinary ( Microalbumin Creatinine )profile analysis
    • Histopathology of kidney
    X
  • In-Vivo Model for Test Item on Diabetes Induced Atherosclerosis
    Model
    Repeated low dose induced diabetes followed by atherogenic diet
    Test System
    Female C57BL6 Mouse
    Method
    • Repeated low dose STZ induction
    • 2-3 week diabetes stabilization
    • Feeding atherogenic diet
    • Test item administration
    • Biochemical analysis
    Test System
    • Body weight, feed consumption
    • Glucose, glycated Hb & Lipid profile analysis
    • Histopathology of aorta strip
    X
  • Wound Healing
    Model
    Wound Healing … In Vivo Model
    Test System
    Wistar rat/ STZ induced diabetic rat
    Method
    • Creation of 1x1 cm wound on dorsal surface
    • Measurement of wound dimension & randomization
    • Wound will be covered with film spray dressing (Cavilon; 3M)
    • Trimethoprim treatment for 5 days
    • Application of test item as per client defined regimen
    • Wound dimension measurement on days 4, 12 and 21 post wounding
    • Sacrifice of representative animals on day 21 for histopathology
    Test System
      Morphometric analysis of wound closure – wound contraction, percent scar areaHistopathology
    • Inflammatory cell infiltration
    • Fibrosis
    • Collagen
    • Fibrin clot
    • Assessment of tensile strength of wound
    X